Waldemar Priebe - 06 Dec 2022 Form 4 Insider Report for CNS Pharmaceuticals, Inc. (CNSP)

Role
10%+ Owner
Signature
/s/ Waldemar Priebe
Issuer symbol
CNSP
Transactions as of
06 Dec 2022
Net transactions value
-$133,114
Form type
4
Filing time
01 Aug 2023, 17:10:16 UTC
Previous filing
25 Jan 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction CNSP Common Stock Sale $13,585 -5,500 -2.2% $2.47 245,605 06 Dec 2022 See footnote F1
transaction CNSP Common Stock Sale $13,530 -5,500 -2.2% $2.46 240,105 07 Dec 2022 See footnote F1
transaction CNSP Common Stock Sale $13,200 -5,500 -2.3% $2.40 234,605 08 Dec 2022 See footnote F1
transaction CNSP Common Stock Sale $6,799 -2,798 -1.2% $2.43 231,807 09 Dec 2022 See footnote F1
transaction CNSP Common Stock Sale $6,450 -5,000 -2.2% $1.29 226,807 10 Mar 2023 See footnote F1
transaction CNSP Common Stock Sale $6,500 -5,000 -2.2% $1.30 221,807 13 Mar 2023 See footnote F1
transaction CNSP Common Stock Sale $6,750 -5,000 -2.3% $1.35 216,807 14 Mar 2023 See footnote F1
transaction CNSP Common Stock Sale $6,100 -5,000 -2.3% $1.22 211,807 15 Mar 2023 See footnote F1
transaction CNSP Common Stock Sale $6,200 -5,000 -2.4% $1.24 206,807 16 Mar 2023 See footnote F1
transaction CNSP Common Stock Sale $5,650 -5,000 -2.4% $1.13 201,807 17 Mar 2023 See footnote F1
transaction CNSP Common Stock Sale $5,400 -5,000 -2.5% $1.08 196,807 20 Mar 2023 See footnote F1
transaction CNSP Common Stock Sale $5,500 -5,000 -2.5% $1.10 191,807 21 Mar 2023 See footnote F1
transaction CNSP Common Stock Sale $5,400 -5,000 -2.6% $1.08 186,807 22 Mar 2023 See footnote F1
transaction CNSP Common Stock Sale $10,800 -10,000 -5.4% $1.08 176,807 23 Mar 2023 See footnote F1
transaction CNSP Common Stock Sale $5,400 -5,000 -2.8% $1.08 171,807 24 Mar 2023 See footnote F1
transaction CNSP Common Stock Sale $5,450 -5,000 -2.9% $1.09 166,807 27 Mar 2023 See footnote F1
transaction CNSP Common Stock Sale $10,400 -10,000 -6% $1.04 156,807 28 Mar 2023 See footnote F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Waldemar Priebe is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may continue.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 Consists of: (i) shares of common stock held by a limited liability company; and (ii) shares held by Houston Pharmaceuticals, Inc.